Analysis of the relation between important baseline clinical and angiographic variables and the occurrence of clinical events in the 308 patients randomised to excimer laser angioplasty (ELCA) or balloon angioplasty (BA)
| Patients | ELCA (%) (n=151) | BA (%) (n=157) | Relative risk (95% CI) | p value |
|---|---|---|---|---|
| Primary clinical end point | 50/151 (33.1%) | 47/158 (29.9%) | 1.11 (0.80 to 1.54) | 0.55 |
| Clinical variables | ||||
| Male | 37/115 (32.1%) | 32/114 (28.1%) | 1.15 (0.77 to 1.70) | 0.50 |
| Female | 13/36 (36.1%) | 15/43 (34.9%) | 1.04 (0.57 to 1.88) | 0.91 |
| ⩾70 years | 11/25 (44.0%) | 11/28 (39.3%) | 1.12 (0.59 to 2.12) | 0.73 |
| <70 years | 39/126 (30.9%) | 36/129 (27.9%) | 1.11 (0.76 to 1.62) | 0.59 |
| Diabetes | 6/15 (40.0%) | 7/20 (35.0%) | 1.14 (0.48 to 2.70) | 0.76 |
| Hypertension | 21/57 (36.8%) | 17/50 (34.0%) | 1.08 (0.65 to 1.81) | 0.76 |
| Hypercholesterolemia | 23/58 (39.7%) | 18/59 (30.6%) | 1.30 (0.79 to 2.14) | 0.30 |
| Smoking status | ||||
| Never | 15/41 (36.6%) | 15/50 (30.0%) | 1.22 (0.68 to 2.19) | 0.51 |
| Previous | 25/74 (33.8%) | 23/68 (33.8%) | 1.00 (0.63 to 1.58) | 1.00 |
| Current | 7/33 (21.2%) | 7/34 (20.6%) | 1.03 (0.41 to 2.62) | 0.95 |
| History of MI | 22/70 (31.4%) | 24/68 (35.3%) | 0.89 (0.56 to 1.43) | 0.63 |
| History of BA | 3/16 (18.8%) | 4/25 (16.0%) | 1.17 (0.30 to 4.56) | 1.00 |
| History of CABG | 3/10 (30.0%) | 2/13 (15.4%) | 1.95 (0.40 to 9.54) | 0.62 |
| Exertional angina | ||||
| CCS class I+II | 16/56 (28.6%) | 15/58 (25.9%) | 1.10 (0.61 to 2.02) | 0.75 |
| CCS class III+IV | 34/95 (35.8%) | 32/99 (32.3%) | 1.11 (0.75 to 1.64) | 0.61 |
| Extent of coronary artery disease | ||||
| Monovessel | 27/83 (32.5%) | 22/79 (27.8%) | 1.17 (0.73 to 1.87) | 0.52 |
| Multivessel | 23/68 (33.8%) | 25/78 (32.1%) | 1.06 (0.66 to 1.68) | 0.82 |
| Lesions | n=158 | n=167 | ||
| Primary clinical end point | 52/158 (32.9%) | 51/167 (30.6%) | 1.08 (0.78 to 1.48) | 0.65 |
| Angiographic variables | ||||
| Location of lesion | ||||
| LAD | 25/61 (40.9%) | 26/64 (40.6%) | 1.01 (0.66 to 1.54) | 0.97 |
| RCA | 15/56 (26.8%) | 19/61 (31.2%) | 0.86 (0.49 to 1.52) | 0.60 |
| LCx | 12/41 (29.3%) | 6/42 (14.3%) | 2.05 (0.85 to 4.94) | 0.08 |
| Type of lesion | ||||
| B2 | 30/83 (36.1%) | 23/71 (32.4%) | 1.12 (0.72 to 1.73) | 0.63 |
| C | 22/74 (29.7%) | 27/94 (28.7%) | 1.04 (0.64 to 1.66) | 0.89 |
| Ulcerated | 17/53 (32.1%) | 15/55 (27.3%) | 1.18 (0.66 to 2.11) | 0.58 |
| Calcified | 9/33 (27.3%) | 10/39 (25.6%) | 1.06 (0.49 to 2.30) | 0.88 |
| Eccentric | 30/100 (30.0%) | 33/104 (31.7%) | 0.95 (0.63 to 1.43) | 0.79 |
| Tandem | 9/18 (50.0%) | 3/26 (11.5%) | 4.33 (1.36 to 13.83) | 0.01 |
| Estimated lesion length | ||||
| 10 to 20 mm | 39/122 (31.9%) | 35/109 (32.1%) | 1.00 (0.68 to 1.45) | 0.98 |
| >20 mm | 12/33 (36.4%) | 11/44 (25.0%) | 1.45 (0.74 to 2.88) | 0.28 |
| Grade of perfusion | ||||
| 0 + I | 15/49 (30.6%) | 12/54 (22.2%) | 1.38 (0.72 to 2.65) | 0.33 |
| II + III | 37/109 (33.9%) | 39/113 (34.5%) | 0.98 (0.68 to 1.42) | 0.93 |
| Quantitative variables | ||||
| Reference diameter (mm) | ||||
| ⩽2.5 | 26/76 (34.2%) | 35/88 (39.7%) | 0.86 (0.58 to 1.29) | 0.46 |
| >2.5 | 23/66 (34.8%) | 13/63 (20.6%) | 1.69 (0.94 to 3.03) | 0.07 |
| Length (mm) | ||||
| <20 | 25/79 (31.6%) | 24/73 (32.9%) | 0.96 (0.61 to 1.53) | 0.87 |
| ⩾20 | 12/35 (34.3%) | 14/50 (28.0%) | 1.22 (0.64 to 2.33) | 0.54 |
| Diameter stenosis (%) | ||||
| ⩽70 | 30/98 (30.6) | 35/106 (33.0%) | 0.93 (0.62 to 1.39) | 0.71 |
| 70 to 90 | 7/18 (38.9%) | 4/18 (22.2%) | 1.75 (0.62 to 4.95) | 0.28 |
| >90 | 15/42 (35.7%) | 12/43 (27.9%) | 1.28 (0.68 to 2.40) | 0.44 |
Primary clinical end point: death, myocardial infarction (MI), coronary artery bypass grafting (CABG), repeat angioplasty; CCS, angina classification according to the Canadian Cardiovascular Society classification system;12 LAD, left anterior descending coronary artery; RCA, right coronary artery; LCx, left circumflex coronary artery; Type of lesion, according to the modified ACC/AHA Task Force criteria;13 Grade of perfusion, according to the TIMI study group.10